May 21, 2020
First Light Diagnostics Posters and Abstracts Accepted, Part of ECCMID 2020 Abstract Book
May 19, 2020
MGB Biopharma Announces Successful Outcome From Phase II Clinical Study with MGB-BP-3 - a Potential New Gold Standard, First-line Treatment for Clostridium difficile Infection (CDI)
Mar 13, 2020
Microbiome Therapeutics Innovation Group Statement on Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Events Likely Due to Transmission of Pathogenic Organisms
Feb 10, 2020
US Fecal Microbiome Transplant Market Outlook 2025
Jan 24, 2020
New Published Study Documents Double The Expected Reduction In C.Diff
Jan 15, 2020
Acurx Receives USAN Approval of Non-proprietary Name Ibezapolstat for Its Phase 2 Novel, First-in-Class Antibiotic for C. difficile Infection
Jan 07, 2020
Synthetic Biologics Receives FDA Guidance at Type C Meeting for SYN-004 (ribaxamase) Phase 1b/2a Clinical Trial in Allogeneic HCT Recipients
Nov 04, 2019
Acurx Pharmaceuticals to Present at Two Prominent International Healthcare Conferences
Oct 10, 2019
MGB Biopharma Announces Promising Phase IIa Clinical Trial Update for MGB-BP-3, a Novel, Potent Bactericidal Antibiotic Targeting Clostridium difficile-Associated Diarrhoea (CDAD)
Oct 03, 2019
Acurx's Novel Lead Antibiotic Candidate Presented at Two Prominent International Scientific Conferences
Oct 01, 2019
Microbiome Therapeutics Innovation Group Highlights Member Company Activity at IDWeek 2019
Sep 11, 2019
ANI Pharmaceuticals Announces Launch of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5mL
Aug 30, 2019
MGB Biopharma Announces Completion of Funding Round
Aug 13, 2019
Altapure Partners with Red One Medical to Tackle Disinfection in VA and DoD Facilities
Jun 20, 2019
ANI Pharmaceuticals Announces Approval of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5ml
Mar 26, 2019
CutisPharma Continues Growth Trajectory with Opening of New Corporate Headquarters, Expansion of Manufacturing Site
Mar 14, 2019
MTIG Position Statement for FMT
Feb 27, 2019
Acurx Announces First-In-Man Clinical Trial Data of ACX-362E for CDI
Jan 24, 2019
MGB Biopharma - FDA and Health Canada Clear IND/CTA Applications for MGB-BP-3, a Novel, Potent Bactericidal Antibiotic Targeting Clostridium difficile-Associated Diarrhoea (CDAD)
Jan 16, 2019
Acurx Receives FDA Fast Track Designation for ACX-362E for the Treatment of C. difficile infection